

**RWANDA**  
**SUPPORT for INACTIVATED POLIO VACCINE (IPV)**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Rwanda				
<b>2. Grant Number:</b> 1518-RWA-25c-X / 15-RWA-08h-Y				
<b>3. Date of Decision Letter:</b> 05 February 2015				
<b>4. Date of the Partnership Framework Agreement:</b> 07 June 2013				
<b>5. Programme Title:</b> New Vaccine Support (NVS)				
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)				
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID				
<b>8. Programme Duration<sup>2</sup>:</b> 2015 - 2018				
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b> <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>				
	2015	2016	2017	Total <sup>3</sup>
Programme Budget (US\$)	US\$301,500	US\$670,500	US\$591,500	US\$1,563,500
<b>10. Vaccine Introduction Grant:</b> US\$338,000				
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>				
Type of supplies to be purchased with Gavi funds in each year	2015	2016		
Number of IPV vaccines doses	259,600	577,500		
Number of AD syringes	239,900	524,500		
Number of safety boxes	2,650	5,775		
Annual Amounts (US\$)	US\$301,500	US\$670,500		
<b>12. Procurement agency:</b> UNICEF				

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2017.

<sup>4</sup> This is the amount that Gavi has approved.

<b>13. Self-procurement:</b> N/A					
<b>14. Co-financing obligations:</b>  Gavi's usual co-financing requirements do not apply to IPV. However, Rwanda is encouraged to contribute to vaccine and/or supply costs for IPV.					
<b>15. Operational support for campaigns:</b> N/A					
<b>16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:</b>					
<table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or equivalent</td> <td>As agreed with the secretariat</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or equivalent	As agreed with the secretariat
Reports, documents and other deliverables	Due dates				
Annual Progress Report or equivalent	As agreed with the secretariat				
<b>17. Financial Clarifications:</b> N/A					
<b>18. Other conditions:</b>  If Rwanda envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Rwanda.  Please provide an update on implementation of recommendations indicated in the signed Aide-Mémoire.  Please send a copy of insurance policy certifying that vaccines and devices are insured as stipulated and required by the Partnership Framework Agreement.					

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
05 February 2015